Update shared on 15 Nov 2025
Fair value Increased 11%Red Violet's analyst price target has been raised from $61 to $67.50 per share. This change reflects analysts' increased confidence in the company's improving profit margins and overall positive financial outlook.
What's in the News
- From July 1, 2025 to November 3, 2025, Red Violet repurchased 15,437 shares, representing 0.11 percent of its shares, for $0.65 million. This completes the buyback of 553,921 shares, or 3.98 percent, for $11.08 million under the buyback program initially announced in May 2022 (Key Developments).
- On November 3, 2025, Red Violet increased its equity buyback plan authorization by $15 million, raising the total authorization to $30 million (Key Developments).
Valuation Changes
- The Fair Value Estimate has increased from $61 to $67.50 per share, reflecting a higher valuation.
- The Discount Rate has remained nearly unchanged, moving from 8.41% to 8.41%.
- The Revenue Growth Expectation has decreased marginally, from 14.13% to 13.86%.
- The Net Profit Margin has risen from 11.73% to 12.42%.
- The Future P/E Ratio has increased slightly, moving from 75.72x to 76.00x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.